About one-third of the patients with IBD experienced NAFLD worldwide. The risk of NAFLD was two times higher in IBD patients versus healthy controls. Older age and higher BMI were potentially linked to increased risk of NAFLD in patients with IBD.

Pooled adequate immune response (AIR, >10 IU/L) and effective immune response (EIR, >100 IUL) rates after HBV vaccination in inflammatory bowel disease (IBD) patients were 62% (95% CI, 55–68) and 42% (95% CI, 37–48), respectively. Gender, IBD subtype, and disease activity did not affect the response rate. Use of immunosuppression [immunomodulators (RR: 0.73, 95% CI, 0.62–0.87) and anti-TNFs (RR: 0.72, 95% CI, 0.60–0.87)] was a predictor of poor immune response compared to no immunosuppressive therapy.

These data, together with recommendations from various CHB treatment guidelines, support the concept of switching to TAF in individual patients with CHB, including those at risk of bone or renal complications, elderly patients and those with previous NA treatment.

GLP-1RAs have a variety of hepatic and extra-hepatic physiological effects which may impact the natural history of nonalcoholic fatty liver disease and serve as the rational for potential therapeutic use in this population. GLP-1RA, glucagon-like peptide-1 receptor agonist; NASH, non-alcoholic steatohepatitis.

Surveillance guidelines only benefit the small proportion of patients with Lynch syndrome who are diagnosed after positive testing before potential cancer has developed. For those patients diagnosed, surveillance guidelines should consider pathogenic variant type, underlying mechanisms of mismatch repair deficiency, rates of mutation accumulation, and increasing cancer risk with age.

The diagrams show the time-course of the most common outcomes of (A) HBV-HDV co-infection and (B) HDV super-infection of an HBV carrier. Biochemical and serological parameters are indicated.

A sequential approach using the age-adjusted FIB-4 and VCTE to detect advanced fibrosis in Korean patients with NAFLD.

Prevalence of HFE-relatedhemochromatosis (HC1) and secondary causes of hyperferritinemia and their association with iron overload in 1,059 French patients treated by venesection.

Initial DILI-CAT phenotype for study-drug is derived from few cases with liver injury. Then tested against study-drug to comparator-drug cases with liver injury. Additional cases are used to refine DILI-CAT phenotype, and then tested against additional cases.